AstraZeneca, G42 Healthcare aim to collaborate

By LabPulse.com staff writers

June 21, 2022 -- Abu Dhabi-based G42 Healthcare has signed a letter of intent with AstraZeneca with the aim of expanding their collaboration into diagnostics and clinical research and providing access to treatments for patients in the United Arab Emirates (UAE) and beyond.

According to the Department of Health in Abu Dhabi, G42 Healthcare and AstraZeneca had already signed a declaration of collaboration in December 2021.

The new agreement expands the partnership to build local research capabilities, conduct clinical trials in the UAE, and localize oncology biomarker testing in UAE.

Grail, AstraZeneca to collaborate on companion diagnostic tests
Grail on Thursday announced its strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic (CDx) assays for use with AstraZeneca’s...
Saga inks assay development deal with AstraZeneca
Swedish liquid biopsy and genomic testing provider Saga Diagnostics is developing new digital polymerase chain reaction assays for AstraZeneca.
Thermo Fisher, AstraZeneca to develop NGS companion diagnostics
Thermo Fisher Scientific and AstraZeneca plan to co-develop companion diagnostics based on next-generation sequencing (NGS) to support targeted therapies.

Copyright © 2022 LabPulse.com

Last Updated mp 6/21/2022 11:50:03 AM